Compare CTS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | ZYME |
|---|---|---|
| Founded | 1896 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1994 | 2022 |
| Metric | CTS | ZYME |
|---|---|---|
| Price | $56.65 | $27.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | 192.6K | ★ 499.9K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | 15.87 | ★ 33.33 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $541,318,000.00 | $105,965,000.00 |
| Revenue This Year | $5.55 | $183.10 |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $95.14 | ★ N/A |
| Revenue Growth | 4.95 | ★ 38.87 |
| 52 Week Low | $36.03 | $13.60 |
| 52 Week High | $69.55 | $29.75 |
| Indicator | CTS | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 73.09 |
| Support Level | $54.75 | $22.10 |
| Resistance Level | $59.66 | $29.75 |
| Average True Range (ATR) | 1.87 | 1.10 |
| MACD | -0.89 | 0.57 |
| Stochastic Oscillator | 10.52 | 99.52 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.